1 / 17

New initiatives for TB vaccines

New initiatives for TB vaccines. TBVAC Follow-up to the TB vaccine cluster, led by the Pasteur Institute Goal is to take the best new TB vaccines through phase I and II clinical trials Total grant approx €18 million. MUVAPRED New study, led by Chiron

aya
Download Presentation

New initiatives for TB vaccines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New initiatives for TB vaccines TBVAC Follow-up to the TB vaccine cluster, led by the Pasteur Institute Goal is to take the best new TB vaccines through phase I and II clinical trials Total grant approx €18 million MUVAPRED New study, led by Chiron Goal is to take promising new vaccines for TB and HIV that can be delivered by the oral route through phase I clinical trials Total grant approx €15 million

  2. The Hybrid1 vaccine Ag85B1-285 ESAT-61-95 Ag85B241-260 ESAT-61-20 NVA The Hybrid1 vaccine has been tested in a variety of animal species and in multiple delivery systems. It has been shown to be immunogenic in all species so far tested Epitope mapping with human cells has shown that peptides from these molecules can bind to a wide variety of HLA types and consistent with this, the two proteins are widely recognised in sensitised humans

  3. Survival of vaccinated mice Naive ESAT-6 Ag85B Hybrid 100 BCG 80 Percent survival 60 40 20 0 50 100 150 200 Days post-infection

  4. Survival of vaccinated guinea pigs 120 100 80 % survival 60 Naive BCG 40 Ag85B-ESAT-6 Ag85B 20 dESAT-6 Ag85B+dESAT-6 0 0 5 10 15 20 25 30 Weeks post infection

  5. Boosting of vaccine immunogenicity after 9 months in mice 10 8 6 IFN-g (ng/ml) 4 2 0 Priming: PBS BCG BCG BCG Hybrid Hybrid Boosting: PBS PBS BCG Hybrid PBS Hybrid

  6. Boosting BCG efficacy in guinea pigs

  7. Lung response to oral/nasal vaccination 3000 * * 2000 Lung IFN (pg/ml) 1000 * * 0 Priming: PBS sc oral nasal sc sc Boosting: PBS sc oral nasal oral nasal

  8. Reduction of CFU in lung by oral/nasal vaccination 1.5 * * * 1.0 Log reduction in CFU * * * 0.5 0 Priming: PBS BCG sc oral nasal sc sc Boosting: PBS sc oral nasal oral nasal

  9. Conclusion I • The Hybrid1 vaccine appears to be safe and well tolerated • It is effective as a primary vaccine in mice, guinea pigs and primates • It appears to be effective as a booster vaccine in mice and guinea pigs • It is effective when delivered percutaneously or via the nasal route

  10. 2004 2005 2006 2007 2008 2009 TBVAC timeline GMP production Phase Ia Phase Ib Europe Stability testing Phase Ib Phase II Tox testing Africa Clinical trial design Phase I Clinical trial design Phase II Comparative analysis of new vaccine candidates Phase I Clinical trial design Phase I Europe Comparative analysis of new delivery systems Improved models for memory and lung pathology

  11. 2004 2005 2006 2007 2008 2009 MUVAPRED timeline GMP production Phase Ia Phase Ib Europe Stability testing Phase Ib Phase II Tox testing Africa? Clinical trial design Phase I Clinical trial design Phase II

  12. Does BCG offer only short-term protection in humans? • Meta-analysis of multiple trials suggests that infant vaccination with BCG protects against childhood manifestations of TB for up to 10 years1 • This is supported by recent work showing deferment of TB meningitis in BCG-vaccinated children2 and waning protection in adult vaccinees over time3 Pediatrics 1995 Jul;96(1 Pt 1):29-35 . Colditz GA, et al. Indian J Pediatr 1996 Sep;63(5):659-664. Mittal SK, et al. Scand J Respir Dis 1976;57(5):208-222. Sjogren I.

  13. BCG efficacy - evidence from human trials • BCG is efficient when used in skin test negative donors (Hart and Sutherland 1977) • BCG is efficient when used in neonates (Al-Kassimi 1995; Colditz 1995) • BCG vaccination results in accelerated skin test conversion but rapid waning in areas with environmental exposure - and more sustained responses in areas with low sensitization (Palmer 1952)

  14. BCG - Replace or Repair? These studies suggest that BCG works in naive donors (such as infants) but fails over time, and is ineffective in adults This means that: Stopping infant vaccination with BCG would be ethically difficult There is a place for a vaccine targetted to adults, which could supplement rather than replace BCG

  15. When do we vaccinate? % BCG scar 1% Ethiopia 65% Zambia 70% Gambia 10 20 30 40 50 60 70 Age of patient at admission

  16. The Paradox of the TB Market • Unfortunately, the TB market is not like any other. • While the target population is huge (est. 132 million doses per year) the market size is very small (curr. est. 34 million € per year) • This is because: • BCG is very cheap (0.28 € per dose) • Disease - and therefore vaccine use - is highest in the poorest countries • Moreover, the chronic nature of the disease means that phase III trials will be very expensive - in the range of 50 - 80 million €

  17. Bringing a TB Vaccine to Market Given the cost issue, a TB vaccine will have to be approached differently from a conventional vaccine/pharmaceutical if commercial development is to be successful Public assistance will be essential for development - in this regard, the EC proposes making approximately 300 million € available in its clinical trial platform, in which TB vaccine development is a priority Staggered pricing regimens (for example, 50€ in the developed world and 4€ in the developing world) would swell the world market to approx 600 million €. This is in principle acceptable to regulatory authorities

More Related